Navigation Links
VentiRx Pharmaceuticals Publishes Preclinical Data of Novel TLR8 Agonist, VTX-2337, Supporting Its Potential as an Immunotherapeutic Approach in Cancer
Date:1/23/2012

SEATTLE, Jan. 23, 2012 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of novel Toll-like receptor 8 (TLR8) agonists for the treatment of cancer, today announced the publication of preclinical data demonstrating that VTX-2337, the Company's lead small molecule, is a novel, highly potent and selective TLR8 agonist. VTX-2337 directly activates human myeloid dendritic cells (mDCs), monocytes and natural killer (NK) cells resulting in the production of high levels of mediators known to orchestrate adaptive anti-tumor responses. Data were published in the journal Clinical Cancer Research.

(Logo: http://photos.prnewswire.com/prnh/20120123/SF39404LOGO)

The findings clearly distinguish TLR8 from other human TLRs. TLR8 is expressed on human monocytes, macrophages and mDCs circulating in blood and lymph nodes as well as on dendritic cells that are prevalent throughout the tumor microenvironment. Results demonstrate that the direct activation of mDCs by VTX-2337 results in a uniquely robust production of inflammatory cytokines and chemokines that increase cell mediated immunity and potentially enhance the anticancer effect of standard chemotherapy. Additionally, VTX-2337 has a direct effect on NK cells and augments antibody dependent cellular toxicity (ADCC), which supports the opportunity of combining VTX-2337 with monoclonal antibodies where ADCC contributes to clinical efficacy.

"These preclinical findings underscore the potential of a TLR8 agonist as a promising novel agent for cancer immunotherapy," said Mary L. Disis, M.D., professor of medicine in oncology at the University of Washington and associate dean of translational science at the UW School of Medicine, and co-author of the publication. "This research provides validation for current clinical trials evaluating VTX-2337 in combination with existing cancer treat
'/>"/>

SOURCE VentiRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
2. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
3. FierceBiotech Names VentiRx Pharmaceuticals as One of the Fierce 15 Biotech Companies of 2010
4. VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... India , July 31, 2015 ... CRM solutions for video, data and cloud computing ... with a leading pharma giant for Internet of ... different IoT applications offered on subscription model. ... Pharma giant is striving for business innovations ...
(Date:7/30/2015)... July 30, 2015  ResMed Inc. (NYSE: RMD ... 30, 2015.  Revenue for the quarter was $453.1 million, ... June 30, 2014 (a 17 percent increase on a ... with the quarter ended June 30, 2014.  Diluted earnings ... the quarter ended June 30, 2014.  ...
(Date:7/30/2015)... BOTHELL, Wash. and VANCOUVER ... OGXI ) announced today that it will report ... 13, 2015. Company management will host a conference call ... provide an overview of financial results, clinical development programs ... access the webcast, log on to the Investor Relations ...
Breaking Medicine Technology:Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... Denmark , Feb. 1 LEO Pharma ... mebutate) Gel, the company,s lead candidate for the topical treatment ... primary clinical endpoint of complete clearance of AK lesions in ... AK support results from the earlier REGION-I trial, a study ...
... Ill. and CASTRES, France , Feb. 1 ... licensing agreement with Pierre Fabre SA to develop and commercialize h224G11, ... (CIPF) in France and targeting the cMet receptor for ... progression of a range of solid tumors including, prostate, lung and ...
Cached Medicine Technology:LEO Pharma's PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition 2LEO Pharma's PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition 3Abbott and Pierre Fabre SA Announce Collaboration to Research and Develop Novel Treatments for Cancer 2Abbott and Pierre Fabre SA Announce Collaboration to Research and Develop Novel Treatments for Cancer 3
(Date:8/1/2015)... NY and Greenwich, CT (PRWEB) , ... August ... ... (“Professional”), a Great Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier ... Connecticut — incorporating it into its portfolio of state-of-the-art clinics. , “Our acquisition ...
(Date:8/1/2015)... ... August 01, 2015 , ... BeverlyD, owner and founder of BeverlyD Luxe Organic ... very first small business donation to kick off the campaign for healing and Well-Being. ... legacy includes a complete line of raw, organic hair care products, as well as ...
(Date:7/31/2015)... Santa Rosa, CA (PRWEB) , ... July 31, ... ... been posted by High Times magazine. What are the STASH awards? The ... celebrate advances made by the cannabis-cultivation community as well as tried-and-true products that ...
(Date:7/31/2015)... ... 2015 , ... The Honor Society of Nursing, Sigma Theta Tau International (STTI) ... (GAPFON) 20-21 July 2015 in San Juan, Puerto Rico. Key nurse leaders from Central ... Cassiani, Advisor, Nursing and Allied Health Personnel Development, Unit of Human Resources for Health, ...
(Date:7/31/2015)... ... ... Precision Aesthetics is New York’s only Thermage skin tightening pinnacle and black diamond award ... fat reduction in New York. Due to its unparalleled level of experience for ... patients travel to New York to get their non-surgical skin tightening and body shaping ...
Breaking Medicine News(10 mins):Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4
... FORT WORTH, Texas, Nov. 11 Wound Management ... Management Technologies Division will search for partners to ... to develop opportunities within the International Biotechnology and ... developments concerning advisory board appointments, research affiliations, and ...
... FAIRFAX, Va.Catheter-directed therapy or catheter-directed thrombolysisan interventional radiology ... specially designed catheters to dissolve dangerous blood clots ... a first-line treatment option for massive pulmonary embolism, ... Vascular and Interventional Radiology . "Modern ...
... ... announces new research focusing on Employee Engagement, Revenue and the New Economy as kickoff ... ... 12, 2009 -- There is little else more pressing in business than the financial ...
... ... decades The American Red Cross is making available for sale to the ... and bound journals, antique uniforms (1925 – 1941), flags, vintage ... a model train, photographs (including those of the founder Clara Barton, past ...
... The Quigley Corporation, (Nasdaq: QGLY) , ... a conference call in which Ted Karkus, Chairman and CEO, will ... results and Q&A. , The conference call will be ... www.quigleyco.com ), at 11:00 AM (ET) on Thursday, November 12, ...
... , LONDON, Nov. 11 The healthcare market is ... the global economic slowdown. Costs for healthcare are reaching ... exception. Market players in this industry have been faced ... technological advancements in hardware, high replacement costs, exchange rates ...
Cached Medicine News:Health News:OTCBB-WNDM Announces Activation of BioPharma Division to Solicit Technology and Development Partners 2Health News:OTCBB-WNDM Announces Activation of BioPharma Division to Solicit Technology and Development Partners 3Health News:When seconds count: Interventional radiology treatment for pulmonary embolism saves lives 2Health News:When seconds count: Interventional radiology treatment for pulmonary embolism saves lives 3Health News:Performance Connections International Announces New Research Focusing on the Impact of Employee Engagement in the New Economy 2Health News:Performance Connections International Announces New Research Focusing on the Impact of Employee Engagement in the New Economy 3Health News:American Red Cross Auctions Historical Artifacts Through OLS Trading, Inc 2Health News:American Red Cross Auctions Historical Artifacts Through OLS Trading, Inc 3Health News:The Quigley Corporation to Host Conference Call to Review Third Quarter Results and Provide Company Update 2Health News:Frost & Sullivan to Hold Analyst Briefing on the European Neurophysiological Monitoring Market, the Golden Standard in Patient Safety 2Health News:Frost & Sullivan to Hold Analyst Briefing on the European Neurophysiological Monitoring Market, the Golden Standard in Patient Safety 3
The SF-3000 automated hematology analyzer can provide accurate and precise 23-parameter hematolgy results including a fully automated WBC 5-part differential from a compact space-save design....
Ac.T 5diff CP allows quick and direct access to a closed sample tubea feature that reduces manual sample handling, saves time and enhances safety by eliminating operators exposure to biohazards....
... 755 simplifies and automates high-volume ... automation and advanced technologies into ... accurate results every time. Plus, ... quality with its slide-on-slide smearing ...
... The CX31 continue ... of the CH2 microscopes ... arenas, now with UIS ... models improve all-around performance ...
Medicine Products: